1. Home
  2. BBNX vs NGNE Comparison

BBNX vs NGNE Comparison

Compare BBNX & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

HOLD

Current Price

$16.49

Market Cap

493.1M

Sector

Health Care

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$35.40

Market Cap

498.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBNX
NGNE
Founded
2015
2003
Country
United States
United States
Employees
423
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.1M
498.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BBNX
NGNE
Price
$16.49
$35.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
7
Target Price
$23.80
$63.57
AVG Volume (30 Days)
1.1M
233.2K
Earning Date
04-21-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.93
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$34.90
N/A
Revenue Next Year
$34.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.80
$15.93
52 Week High
$32.71
$37.27

Technical Indicators

Market Signals
Indicator
BBNX
NGNE
Relative Strength Index (RSI) 65.40 68.81
Support Level $16.02 $19.27
Resistance Level $32.52 $36.37
Average True Range (ATR) 1.07 2.05
MACD 0.14 0.39
Stochastic Oscillator 83.89 95.22

Price Performance

Historical Comparison
BBNX
NGNE

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: